Skip to main content

Table 5 Parameters from ROC analysis on serum Trx1, CEA, and CA15-3 levels in patients with breast cancer

From: Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses

BC Grade

AUC* (±SEM)

Sensitivity (%)

Specificity (%)

Criterion** Value

# of serum (# of L:-D) §

BC_Total

0.901 ± 0.0252

89.8

78.0

>32.1725

197 (106:91)

0.678 ± 0.0408

54.4

77.6

>8.28

0.179 ± 0.0359

48.6

89.8

>29.8227

BC I

0.837 ± 0.0399

89.4

72.0

-

66 (35:31)

0.594 ± 0.0523

30.3

89.8

-

0.693 ± 0.0482

50.0

83.7

-

BC II

0.908 ± 0.0270

82.9

86.0

-

70 (37:33)

0.692 ± 0.0478

56.8

77.6

-

0.673 ± 0.0480

44.8

89.8

-

BC III

0.962 ± 0.0156

88.5

92.0

-

61 (34:27)

0.762 ± 0.0460

66.7

77.6

-

0.794 ± 0.0411

60.6

89.8

-

Normal

-

-

-

-

50 (NF)

  1. *P < 0.0001.
  2. **Units of criterion values represent as ng/ml for Trx1 and CEA or U/ml for CA15-3.
  3. Upper, middle, and lower values in each row are those for Trx1, CEA, and CA 15–3, respectively.
  4. §L and D are lobular and ductal carcinoma of breast cancer respectively.